Hedge Funds Have Never Been This Bullish On ACADIA Pharmaceuticals Inc. (ACAD)
We hate to say this but, we told you so.
Acadia Pharmaceuticals Inc (ACAD)
Market is closed
News
- First
- << Previous
- 41 - 50
- Next >>
How Did ACADIA Pharmaceuticals Inc. (ACAD) Perform In Comparison to Hedge Fund Favorites in 2019?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Hedge Funds Snapped Up ACADIA Pharmaceuticals Inc. (ACAD) Before The Q4 Rally
The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China.
Hedge Funds Are Betting On ACADIA Pharmaceuticals Inc. (ACAD) Again
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Hedge Fund and Insider Trading News: Ken Griffin, Tom Steyer, Amber Capital, Acadia Pharmaceuticals Inc. (ACAD), and More
PARIS (Reuters) - Activist shareholder Amber Capital, which is being sued by Lagardere (LAGA.PA), said on Monday the lawsuit was baseless and it would continue to seek strategy and management changes ...
Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies...
Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. (ACAD)?
Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.
Is ACADIA Pharmaceuticals Inc. (ACAD) A Good Stock To Buy?
"Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing.
Hedge Fund and Insider Trading News: Crispin Odey, Third Point LLC, Criterion Capital, Twitter Inc (TWTR), ACADIA Pharmaceuticals Inc. (ACAD), and More
Crispin Odey, whose bearish bets led to his hedge fund suffering three successive years of losses, is firmly back on the rise. The Odey European Inc.
13D Filing: Baker Bros. Advisors and Acadia Pharmaceuticals Inc (NASDAQ:ACAD)
Baker Bros. Advisors purchased about 1.2 million shares of Acadia Pharmaceuticals Inc (NASDAQ:ACAD) for about $19 per share last week.
- First
- << Previous
- 41 - 50
- Next >>
Billionaire Hedge Funds
